Introduction {#s1}
============

Changes in technologies, treatments, medical knowledge, and cultural norms provide cause to review and change disease definitions and diagnostic thresholds, a task that is commonly undertaken by expert panels, consensus meetings, or influential workgroups who publish findings as statements, special reports, or as part of clinical practice guidelines. While such changes can be beneficial, there is an increasing recognition that widening of disease definitions may be one factor contributing to the problem of over-diagnosis, occurring across a range of conditions including pulmonary embolism, breast and prostate cancers [@pmed.1001500-Welch1],[@pmed.1001500-Hoffman1]. The concern expressed by some researchers is that for some people with milder symptoms, at lower risks, or in earlier stages of possible disease, the harms of a diagnostic label and treatment may outweigh benefits [@pmed.1001500-Moynihan1],[@pmed.1001500-Brody1].

At the same time there is accumulating evidence about pervasive financial ties between pharmaceutical companies and health professionals [@pmed.1001500-Lo1], including those writing guidelines [@pmed.1001500-Norris1] and disease definitions [@pmed.1001500-Cosgrove1]. While noting the value of professional--industry collaborations, a 2009 Institute of Medicine (IOM) report found "widespread relationships with industry have created significant risks that individual and institutional financial interests may unduly influence professionals\' judgments," and that these "conflicts of interest" threaten the integrity of research, the objectivity of education, the quality of patient care, and public trust in medicine [@pmed.1001500-Lo1].

The 2009 report recommended professional societies and other organisations drafting clinical practice guidelines should "generally exclude as panel members individuals with conflicts of interest." A subsequent 2011 IOM report on how to produce trustworthy guidelines included recommendations that "whenever possible," guideline developers "should not have" conflicts of interest, that only a minority should have conflicts, and that chairs should be free of conflicts [@pmed.1001500-IOM1].

As both reports make clear, in addition to financial ties there are non-financial or intellectual conflicts such as academic advancement, and there should be no assumption that having a conflict is unethical, or "that any particular professional will necessarily let financial gain influence his or her judgment" [@pmed.1001500-Lo1].

A 2011 systematic review found many clinical guideline panels have failed to disclose financial ties, and those that did disclose had a "high percentage" of individuals with financial conflicts of interest [@pmed.1001500-Norris1]. Studies analysing ties of working groups for the Diagnostic and Statistical Manual of Mental Disorders (DSM), which set definitions and diagnostic criteria, have also found a majority of members with ties [@pmed.1001500-Cosgrove1]. Kung and colleagues recently found two-thirds of individuals chairing guideline committees had conflicts of interest [@pmed.1001500-Kung1].

Few studies [@pmed.1001500-Cosgrove1] have examined the financial ties of members of panels reviewing and changing definitions of common conditions, whether as part of practice guideline development or other processes. Our aim was to identify guideline panels in the US setting that have most recently made decisions about definitions or diagnostic thresholds for common conditions, and to report on any proposed changes and their industry ties.

Methods {#s2}
=======

List of Conditions {#s2a}
------------------

On the basis of the method previously used by Choudhry and colleagues [@pmed.1001500-Choudry1], we derived a list of common conditions in the United States, drawing from a list of the ten most costly adult diseases [@pmed.1001500-Soni1], the top 20 therapeutic classes of drugs, and the top 25 individual drugs by expenditure [@pmed.1001500-IMS1]. Consistent with that method, drugs used to treat many non-specific conditions were excluded (e.g., pain killers). For situations in which a drug was approved for a number of conditions, we identified the most common condition for inclusion (e.g., etanercept ultimately mapped to rheumatoid arthritis, not psoriatic arthritis). If a condition in the top ten costly disease list was too broad or diffuse, or covered many specific conditions, it was excluded (e.g., back problems). A flowchart of the method appears in [Figure 1](#pmed-1001500-g001){ref-type="fig"}.

![Flowchart identifying study conditions and panels reviewing definitions.\
Note: bipolar/depression was one panel.](pmed.1001500.g001){#pmed-1001500-g001}

List of Panels and Publications {#s2b}
-------------------------------

We aimed to identify the most recent publication from panels making decisions about disease definition and diagnosis. A panel publication was eligible for inclusion if it was generated or supported by a widely recognised US-based organisation, published between 2000 and April 2013, and included deliberations and decisions on disease definitions and/or diagnostic criteria, classification, or assessment. If the panel made decisions, but proposed no changes, our search would continue for the most recent publication proposing changes, to include as well. If the focus of the panel publication was limited to specific sub-groups of patients, (e.g., adolescents), specific sub-categories of the condition (e.g., work-related asthma), it came from a single entity (e.g., a health maintenance organisation), or it included treatment recommendations but no review and deliberation on disease definition or diagnostic criteria, it was excluded.

During a pilot phase, using the searches for the most recent hypertension and asthma panel publications, an explicit search strategy using standardized keywords was iteratively developed in order to maximise sensitivity. We searched Medline (Ovid) using terms for each disease/condition and combined these terms with a standardized search strategy consisting of a string of MeSH and keyword terms to identify panels and publications (example in [Table S1](#pmed.1001500.s001){ref-type="supplementary-material"}). Searches were run over 26--31 July 2012, updated 17--18 April 2013, and limited to English language from 2000.

To further improve sensitivity and try to ensure recent publications were not missed, two authors (RNM, GPEC) independently analysed the results of the standardised Medline searches for all conditions, and supplemented this with independent individual searches of the websites of the relevant National Institutes of Health and the National Guideline Clearing House. For two conditions, minor discrepancies in independent suggestions were resolved by discussion and, in one case (diabetes II), by consultation with a third author (PPG). Because of their global prominence and influence, if a panel was constituted under the umbrella of the National Institutes of Health (NIH), or the American Psychiatric Association\'s DSM, and met our inclusion criteria, these panels were identified for inclusion in our study. If there was a more recent panel publication that also met the study\'s inclusion criteria, in addition to the NIH or DSM panel, we included the more recent publication as well. This occurred twice (asthma and high cholesterol), resulting in two publications being identified for each condition.

Information on the Panels\' Decisions {#s2c}
-------------------------------------

For each publication we extracted information on key proposed changes to definitions/diagnostic criteria, the rationale offered, and any mention of potential harms associated with the proposed changes (e.g., over-diagnosis, overtreatment, medicalizing normality, labelling asymptomatic people). All six authors then made an assessment of whether the panel\'s proposed key changes would tend to widen (e.g., earlier diagnosis, lower thresholds, adding symptoms, increasing numbers diagnosed) or narrow the disease definition, or whether it was unclear.

Information on Industry Ties {#s2d}
----------------------------

Using published disclosure sections from the panel publications, duplicate independent extraction of data was conducted (RNM and research assistant Peter Coxeter), with a third party resolving any disagreement (PGG). Ties were categorized as speaker/honorarium, consultant/adviser, grant/research, stock, employee, travel, or royalties. Panel members were those listed as authors or identified as the group with primary responsibility for generating the publications. In line with the IOM approach [@pmed.1001500-Lo1], an industry tie was defined as a tie to a pharmaceutical, diagnostic, device, or biotechnology company, but not a communications or medical education company. If there was any lack of clarity as to the nature of the company, or uncertainty if it met study criteria, a tie was not recorded. Once all industry ties were recorded for each panel, websites of companies with financial ties to the three highest proportions of panel members were searched to determine whether those companies were active in the specific therapeutic area. Where they appeared in disclosure sections, the disclosure of any ties to public agencies, non-government organizations, and publishers was also recorded.

Results {#s3}
=======

After analyzing source documents [@pmed.1001500-Soni1],[@pmed.1001500-IMS1], the following drug classes, individual drugs, and conditions were excluded when identifying study conditions, as they were too non-specific or too broad, and did not map to specific conditions enabling analysis: oncologics; autoimmune diseases; narcotic analgesics; anti-epileptics; vaccines; hormonal contraceptives; immunostimulating agents; bevacizumab; oxycodone; pegfilgrastim; cancer; trauma-related disorders; and back problems.

From an initial list of 16 included common conditions, for two---osteoarthritis, HIV---we could identify no panel that made decisions about definitions or diagnostic thresholds since 2000 in the US context specifically. For the remaining 14 conditions, we identified the most recent panels that deliberated and made decisions about disease definitions, all of which proposed changes. For asthma and high cholesterol we identified two panels each, one constituted under the government funded NIH [@pmed.1001500-National1],[@pmed.1001500-National2] and one by professional societies [@pmed.1001500-Reddel1],[@pmed.1001500-Jellinger1], reflecting the two main types of panels identified in this study. A single panel, the DSM-V Mood Disorders working group, proposed changes to two different conditions, bipolar and depression, in two separate web-based publications [@pmed.1001500-The1]. A full list of the final 14 conditions, 15 panels and 16 publications, key changes and rationale, analysis of panel decisions, and disclosed ties appears in [Table 1](#pmed-1001500-t001){ref-type="table"}.

10.1371/journal.pmed.1001500.t001

###### Conditions and characteristics of the panels and publications included in the study.

![](pmed.1001500.t001){#pmed-1001500-t001-1}

  Disease                                                                     Panel                                                   Change/s                                             Rationale                         Widens or Narrows?   Mentions Risk?   Discloses?   Ties?   Chair Ties?   For Members with Ties, Mean Numbers:   Percent Members Disclosing Non-Industry Ties        
  --------------------------------------------- ----------------------------------------------------------------- ------------------------------------------------- ------------------------------------------------------- -------------------- ---------------- ------------ ------- ------------- -------------------------------------- ---------------------------------------------- ----- -----
  ADHD                                                          DSM V 2012 [@pmed.1001500-ADHD1]                         Changes onset age; expands symptoms         Help facilitate adult diagnosis; previous age invalid         Widen                y              y          y          n                         2                                         1.2                        1.8   78
  Alzheimer                                      NIA-AA 2011 [@pmed.1001500-McKhann1]--[@pmed.1001500-Sperling1]               Creates new categories                        Update; new evidence about biomarkers                 Widen                y              y          y          y                         0                                         4.5                        0.9   13
  Anemia/CKD                                                    KDIGO 2012 [@pmed.1001500-KDIGO1]                                Narrows definition                                    In line with WHO                            Narrow               n              y          y          y                        0.9                                        2.3                        1.2   n/a
  Asthma                                                      ATS/ERS 2009 [@pmed.1001500-Reddel1]                              Redefines "severity"                                        Complex                               Unclear               n              y          y          y                        2.9                                        5.3                        4.3   13
  Asthma                                                      EPR 3 2007 [@pmed.1001500-National1]                 New classification; removes "mild-intermittent"                          Complex                               Unclear            unclear           y          y          y                        3.3                                        6.4                        4.1   39
  Bipolar                                                        DSM V 2012 [@pmed.1001500-The1]                          Adds core symptom, new sepcifier                                  Complex                               Unclear               y              y          y          y                        2.1                                         3                         1.8   83
  Depression[a](#nt101){ref-type="table-fn"}                               DSM V 2012                                       Removes bereavement exclusion                         Exclusion was not justified                      Widen                y                                                                                                                                        
  Cholesterol[b](#nt102){ref-type="table-fn"}                ATP III 2002 [@pmed.1001500-National2]                              Changes thresholds                                  Risk of future events                         Widen                n             n/a        n/a        n/a                       n/a                                        n/a                        n/a   n/a
  Cholesterol                                                 AACE 2012 [@pmed.1001500-Jellinger1]                         Recommends additional new test                       Evidence test can predict risk                     Widen                n              y          y          y                        3.6                                        2.1                        1.4   n/a
  COPD[c](#nt103){ref-type="table-fn"}                          GOLD 2011 [@pmed.1001500-Global1]                   Changes diagnostic method and classification               Simplicity; old system inadequate                  Unclear               y              y          y          y                        n/a                                        n/a                        n/a    8
  Diabetes II[d](#nt104){ref-type="table-fn"}       International Expert Committee 2009 [@pmed.1001500-The2]          Changes diagnostic method; new cut-points          Better test; cut-point related to future risk            Unclear               y              y          n          n                        n/a                                        n/a                        n/a   n/a
  GERD[e](#nt105){ref-type="table-fn"}                   Montreal Definition 2006 [@pmed.1001500-Vakil1]                  New definition and classification                Better for research, simplify management                Widen                n              y          y          y                        n/a                                        n/a                        n/a   n/a
  Hypertension                                                 JNC7 2003 [@pmed.1001500-National3]                         Creates new diagnostic category                       Risk of future complications                      Widen                n              y          y          y                        4.9                                        6.7                        6.9   27
  MS                                                 2010 Revision McDonald Criteria [@pmed.1001500-Polman1]           Changes imaging criteria for diagnosis                 Simplify diagnosis, reduced testing                  Widen                n              y          y          y                        2.6                                        6.1                        2.7   83
  MI[f](#nt106){ref-type="table-fn"}                   Universal Definition 2012 [@pmed.1001500-Thygesen1]             Changes to criteria and classification                 Development of more sensitive tests                  Widen                y              y          y          y                        n/a                                        n/a                        n/a   21
  RA[g](#nt107){ref-type="table-fn"}                        ACR/ELARCI 2010 [@pmed.1001500-Aletaha1]                          New classification system                   Early intervention; consistency in research              Widen                n              y          y          y                        n/a                                        n/a                        n/a    3

The same Mood Disorders work group proposed separate changes to bipolar and depression.

The cholesterol 2002 panel publication was silent on disclosure.

The COPD panel did not separate speaker and consultant ties.

The diabetes panel disclosed no ties.

GERD panel disclosures only pertained to one company and did not include separate categories.

The myocardial infarction panel reported ties in a method that did not allow categorization of different forms of tie.

The rheumatoid arthritis panel did not separate all speaker and consultant ties.

MI, myocardial infarction; MS, multiple sclerosis; n/a, not available; RA, rheumatoid arthritis.

Among 16 publications, all authors in our study agreed that proposals in ten publications would tend to widen definitions ([Table 2](#pmed-1001500-t002){ref-type="table"}) and for one, narrow the definition. For the remaining five publications the impact was unclear. Rationales for the benefits of widening definitions or expanding diagnostic categories included: evidence about the risk of future adverse events for people previously considered normal (pre-hypertension); simplification (gastroesophageal reflux disease \[GERD\]); standardisation for research (rheumatoid arthritis); and the emergence of new evidence about biomarkers, tests, or treatments (Alzheimer disease). Among 15 panels, six included mention of possible harms of proposed changes ([Table 3](#pmed-1001500-t003){ref-type="table"}), albeit briefly, with three of those including citations in that mention [@pmed.1001500-The1]--[@pmed.1001500-ADHD1], two citing primary studies [@pmed.1001500-Global1],[@pmed.1001500-ADHD1], and one of those citing a review of primary studies as well [@pmed.1001500-Global1]. One publication referred to the potential negative consequences for those who would be labelled by the expanded definition [@pmed.1001500-Thygesen1], and only one referred to overdiagnosis [@pmed.1001500-Vakil1].

10.1371/journal.pmed.1001500.t002

###### Different ways to expand disease definitions.

![](pmed.1001500.t002){#pmed-1001500-t002-2}

  Method of Widening                                       Disease                                       Details
  ------------------------------------------------ ----------------------- -------------------------------------------------------------------
  Creating new categories of pre-disease                Hypertension                           Describes pre-hypertension
                                                      Alzheimer disease     Describes pre-dementia and defines pre-clinical Alzheimer disease
  Lowering diagnostic thresholds                    High cholesterol 2002            Lowers cholesterol and triglyceride thresholds
                                                            ADHD                         Changes age of onset; adds new symptoms
                                                         Depression                           Removes bereavement exclusion
                                                            GERD                         Drops severity threshold for definition
  Earlier diagnosis, different diagnostic method    Rheumatoid arthritis                            Earlier diagnosis
                                                     Multiple sclerosis               Single scan diagnosis, earlier identification
                                                    Myocardial Infarction             More sensitive tests identifying more people
                                                    High cholesterol 2012                          Additional new test

10.1371/journal.pmed.1001500.t003

###### Mention of possible harms of proposed changes to definitions.

![](pmed.1001500.t003){#pmed-1001500-t003-3}

  Condition                                                                                                                                                                           Panel Comments
  -------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ADHD [@pmed.1001500-ADHD1]                                                                                                                  "main potential negative consequence of raising the age of onset is an increase in prevalence"
  Alzheimer disease [@pmed.1001500-Sperling1]                                                                                             "ethical and practical implications" of a "diagnosis" of AD at preclinical stage "need to be studied"
  COPD [@pmed.1001500-Global1]                                                               tests "may lead to more frequent diagnosis of COPD in older adults... as the normal process of aging affects lung volumes and flows, and may lead to under-diagnosis in adults younger than 45"
  Diabetes II [@pmed.1001500-The2]                                                              need to balance "stigma and costs of mistakenly identifying individuals as diabetic against the minimal clinical consequences of delaying the diagnosis in someone with an A1C level 6.5%"
  Mood Disorders panel (Bipolar and Depression) [@pmed.1001500-The1]    to prevent "medicalization of normal fluctuations of mood" diagnoses should only be applied when the "clinician determines that the symptoms are associated with clinically significant distress or impairment that require clinical care"
  Myocardial infarction [@pmed.1001500-Thygesen1]                                         "the current modification of the definition of MI may be associated with consequences for the patients and their families in respect of psychological status, life insurance, professional career..."

Note: for all other panel publications we could identify no mentions.

The average number of panel members was 21 (range, five to 52). Among 15 panels, 12 included members disclosing financial ties to multiple companies, one panel disclosed ties to a single company only (GERD) [@pmed.1001500-Vakil1], one stated that members had no relevant conflicts of interest (diabetes II) [@pmed.1001500-The2], and one had no disclosure section (high cholesterol 2002) [@pmed.1001500-National2], also the oldest panel. For a total of 2,081 individual ties across all categories recorded in the study, there were 55 discrepancies, 2.6%, arising from the independent extraction, mainly involving one or other extractor accidentally missing or adding a specific tie, or making errors by entering a specific tie into an adjacent column or row in a spreadsheet. All were resolved by discussion.

Among 14 panels with disclosure sections, the average proportion of members with industry ties was 75% (range 0%--100%) ([Table 4](#pmed-1001500-t004){ref-type="table"}). For members with ties, the median number of pharmaceutical or device companies to which they had declared ties to was seven ([Table 4](#pmed-1001500-t004){ref-type="table"}). For the nine panel publications disclosing multiple separate categories of tie, on average, members with industry ties were a consultant/adviser for four companies, received speaker fees/honoraria from two companies, and they or their institutions received research support from three. Twelve panels were chaired or publications led by authors with industry ties, most commonly to multiple companies. Among panels disclosing any ties to government agencies, non-government organisations, or publishers, on average around one-third of panel members disclosed these ties.

10.1371/journal.pmed.1001500.t004

###### Nature and extent of disclosed ties, by panel.

![](pmed.1001500.t004){#pmed-1001500-t004-4}

  Panel                                                                         Total Number of Industry Ties by Category[a](#nt110){ref-type="table-fn"}   Percent Members with Industry Ties   Median *n* (IQR) Companies Tied to   Percent Members with Non-Industry Ties[c](#nt112){ref-type="table-fn"}                               
  ---------------------------------------------------------------------------- --------------------------------------------------------------------------- ------------------------------------ ------------------------------------ ------------------------------------------------------------------------ -------------- ------------- -------------
  ADHD 2012 [@pmed.1001500-ADHD1]                                                                                  10                                                       6                                    9                                                      2                                       5/9 (56%)      2 (2--5)      7/9 (78%)
  Alzheimer disease 2011 [@pmed.1001500-McKhann1]--[@pmed.1001500-Sperling1]                                        1                                                      117                                   23                                                     10                                     26/46 (57%)     5 (2--7)     6/46 (13%)
  Anemia/CKD 2012 [@pmed.1001500-KDIGO1]                                                                           14                                                       34                                   18                                                     5                                      15/17 (88%)     3 (2--4)         n/a
  Asthma 2009 [@pmed.1001500-Reddel1]                                                                              67                                                      121                                   99                                                     6                                      23/24 (96%)     6 (5--10)    3/24 (13%)
  Asthma 2007 [@pmed.1001500-National1]                                                                            53                                                      103                                   66                                                     0                                      16/18 (89%)     7 (5--11)    7/18 (39%)
  Bipolar; depression 2012 [@pmed.1001500-The1]                                                                    17                                                       24                                   14                                                     6                                       8/12 (67%)     5 (3--6)     10/12 (83%)
  Cholesterol 2012 [@pmed.1001500-Jellinger1]                                                                      25                                                       15                                   10                                                     0                                       7/8 (88%)      4 (3--7)         n/a
  COPD 2011[d](#nt113){ref-type="table-fn"} [@pmed.1001500-Global1]                                                n/a                                                     n/a                                  n/a                                                    n/a                                     12/12 (100%)    9 (8--12)     1/12 (8%)
  Hypertension 2003 [@pmed.1001500-National3]                                                                      44                                                       60                                   62                                                     2                                       9/11 (82%)    12 (11--13)   3/11 (27%)
  MS 2010 [@pmed.1001500-Polman1]                                                                                  44                                                      104                                   46                                                     9                                      17/18 (94%)     7 (5--10)    15/18 (83%)
  MI 2012[d](#nt113){ref-type="table-fn"} [@pmed.1001500-Thygesen1]                                                n/a                                                     n/a                                  n/a                                                    n/a                                     43/52 (83%)     7 (3--12)    11/52 (21%)
  RA 2010[d](#nt113){ref-type="table-fn"} [@pmed.1001500-Aletaha1]                                                 n/a                                                     n/a                                  n/a                                                    n/a                                     17/35 (49%)     7 (5--9)      1/35 (3%)

Individual members can disclose ties to more than one company.

Other = stock, employee, travel, royalties.

Non-industry ties include ties to public agencies, non-government organizations, and publishers; some disclosure sections did not include non-industry ties.

Disclosure sections lumped some categories together.

CKD, chronic kidney disease; IQR, interquartile range; MI, myocardial infarction; MS, multiple sclerosis; n/a, not available; RA, rheumatoid arthritis.

For the 12 panels for which ties were disclosed to more than one company, almost all companies with ties to the three highest proportions of panel members were also active in the market for that panel\'s condition, with at least one drug on the market or in the research pipeline ([Table 5](#pmed-1001500-t005){ref-type="table"}). For example, with the chronic obstructive pulmonary disease \[COPD\] publication, Astra Zeneca, Boehringer-Ingelheim, and GSK---all companies with drugs for the condition---each had financial ties to 11 of 12 members, including the chair [@pmed.1001500-Global1]. With the DSM-V Mood Disorders work group, Pfizer and Lilly---with drugs for depression and bipolar---had ties to five of the 12 members [@pmed.1001500-The1]. Similarly, companies marketing hypertension drugs---Bristol-Myers Squibb, Merck, Novartis---each had financial ties to eight of the 11 members of the panel which created the new diagnostic category "pre-hypertension" [@pmed.1001500-National3].

10.1371/journal.pmed.1001500.t005

###### Companies with highest proportions of ties, and drugs in therapeutic area.
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  Panel[a](#nt115){ref-type="table-fn"}                                    Top Companies   *n* and Percent of Panel to Which Company Had Ties             Drug in Therapeutic Area
  ----------------------------------------------------------------------- --------------- ---------------------------------------------------- ----------------------------------------------
  ADHD [@pmed.1001500-ADHD1]                                               Janssen Cilag                       3/9 (33%)                                    Methylphenidate HCI
                                                                             Eli Lilly                         2/9 (22%)                                      Atomoxetine HCI
                                                                              McNeil                           4/9 (44%)                                    Methylphenidate HCI
                                                                               Shire                           2/9 (22%)                                   Amphetamine (Adderall)
  Alzheimer disease [@pmed.1001500-McKhann1]--[@pmed.1001500-Sperling1]       Pfizer                          13/46 (28%)                                      Donepezil HCI
                                                                             Eli Lilly                        14/46 (30%)                                       Solanezumab
                                                                               Elan                           11/46 (24%)                                       Bapineuzumab
  Anemia/CKD [@pmed.1001500-KDIGO1]                                            Amgen                          13/17 (76%)                                     Darbepoetin alfa
                                                                               Roche                           5/17 (29%)                         Methoxy polyethylene glycol-epoetin beta
                                                                              Affymax                          5/17 (29%)                                       Peginesatide
                                                                               Vifor                           4/17 (24%)                                   Iron supplementation
  Asthma 2009 [@pmed.1001500-Reddel1]                                           GSK                           20/24 (83%)                                  Fluticasone propionate
                                                                                AZ                            19/24 (79%)                                       Zafirlukast
                                                                             Novartis                         14/24 (58%)                                        Omalizumab
  Asthma 2007 [@pmed.1001500-National1]                                         AZ                            11/18 (61%)                                       Zafirlukast
                                                                                GSK                           12/18 (67%)                                  Fluticasone propionate
                                                                               Merck                          13/18 (72%)                                    Montelukast sodium
  Bipolar/depression [@pmed.1001500-The1]                                       AZ                             3/12 (25%)                                   Quetiapine fumerate
                                                                               Lilly                           5/12 (42%)                                  Duloxetine; olanzapine
                                                                              Pfizer                           5/12 (42%)                             Sertraline HCI; ziprasidone HCI
  Cholesterol 2012 [@pmed.1001500-Jellinger1]                                  Merck                           4/8 (50%)                                        Simvastatin
                                                                              Abbott                           3/8 (38%)                                           Niacin
                                                                                AZ                             3/8 (38%)                                        Rosuvastatin
                                                                           Novo-Nordisk                        3/8 (38%)                                            n/a
  COPD [@pmed.1001500-Global1]                                                  AZ                            11/12 (92%)                        Budesonide & formoterol fumarate dihydrate
                                                                                BI                            11/12 (92%)                                    Tiotropium bromide
                                                                                GSK                           11/12 (92%)                                  Fluticasone propianate
  Hypertension [@pmed.1001500-National3]                                        BMS                            8/11 (73%)                                        Irbesartan
                                                                               Merck                           8/11 (73%)                                         Losartan
                                                                             Novartis                          8/11 (73%)                       Amlodipine besylate/benazepril hydrochloride
  Myocardial infarction [@pmed.1001500-Thygesen1]                               AZ                            23/52 (44%)                                       Rosuvastatin
                                                                               Merck                          16/52 (31%)                                       Simvastatin
                                                                               Bayer                          15/52 (29%)                                       Rivaroxaban
                                                                                BI                            15/52 (29%)                                        Alteplase
  Multiple sclerosis [@pmed.1001500-Polman1]                                  Biogen                          13/18 (72%)                                    Interferon beta-1a
                                                                           Merck Serono                       12/18 (67%)                                     Interferon beta
                                                                              Sanofi                          11/18 (61%)                                      Teriflunomide
  Rheumatoid arthritis [@pmed.1001500-Aletaha1]                                 UCB                           15/35 (43%)                                    Certolizumab pegol
                                                                              Abbott                          14/35 (40%)                                        Adalimumab
                                                                                BMS                           13/35 (37%)                                        Abatacept

Analysis not possible for Cholesterol 2002, diabetes, GERD panels.

CKD, chronic kidney disease; n/a, not available.

To evaluate any potential impact of the IOM recommendations regarding industry ties, we compared the panel publications released in 2012---after both IOM reports [@pmed.1001500-Lo1],[@pmed.1001500-IOM1]---to those released earlier. We found similar proportions of members disclosing industry ties (76% was the average across 2012 panels; 74% was the average across pre-2012 panels); a small reduction in the median number of companies to which those members disclosed ties in the 2012 panels (four in 2012 panels; seven pre-2012 panels); and similar proportions of panel publications widening definitions (four of six of 2012 publications; six of ten of pre-2012 publications).

Discussion {#s4}
==========

In this cross-sectional analysis of panels making recent decisions on definitions of common conditions in the US context, we found most panels proposed widening definitions and most had a majority of members with multiple ties to pharmaceutical companies. Proposals to widen fell into three inter-related categories: creating new categories of "pre-disease"; lowering diagnostic thresholds; and proposing earlier diagnosis or different diagnostic methods ([Table 2](#pmed-1001500-t002){ref-type="table"}). In some cases a clear rationale was offered for these changes---as when the hypertension panel cited evidence from original studies and meta-analysis linking normal blood pressure with elevated risks as the reason to create "pre-hypertension" [@pmed.1001500-National3]. In other publications, including the 2007 panel proposing changes to the diagnosis of asthma [@pmed.1001500-National1], the rational was less clear, more complex and diffuse.

Notwithstanding the problem of under-diagnosis, a growing body of evidence suggests over-diagnosis may be occurring across a range of common conditions, including hypertension [@pmed.1001500-Hodgkinson1], asthma [@pmed.1001500-Aaron1], attention deficit hyperactivity disorder (ADHD) [@pmed.1001500-Morrow1], and COPD [@pmed.1001500-Hardie1]. Yet less than half of the study publications mentioned potential harms of proposed changes to definitions, and none included a rigorous evidence-informed discussion of those risks or how they might be mitigated.

In a three-part publication in 2011 [@pmed.1001500-McKhann1]--[@pmed.1001500-Sperling1] proposing new categories of "pre-clinical" Alzheimer disease (for research only at this stage) and "predementia"---which would clearly expand the population labelled---there was one short reference to the need to study the "ethical and practical implications" of diagnosing people at a "preclinical" stage [@pmed.1001500-Sperling1]. The panel proposing changes to assessment and classification of COPD briefly mentioned that diagnostic methods "may lead to more frequent diagnosis of COPD in older adults with mild COPD as the normal process of aging affects lung volumes and flows" [@pmed.1001500-Global1], but did not explicitly refer to the risk of "over-diagnosis" as it had done in a previous version of its report [@pmed.1001500-Global2]. Proposing changes to ADHD diagnostic criteria---in part to make the condition more amenable to being a "lifespan" disorder involving adults as well as children---the DSM-V panel mentioned potential increases in prevalence but suggested they would be "negligible" ([Table 3](#pmed-1001500-t003){ref-type="table"}) [@pmed.1001500-Rationale1].

Among panels disclosing ties, almost all chairs had financial ties to industry, and an average of three-quarters of members had ties to a median of seven companies, commonly working as consultants, advisers and/or speakers, as well as receiving research support. Companies with financial relationships with the greatest proportion of panel members were marketing or developing drugs for the same conditions about which those members were making critical judgements. GSK for example, marketing top-selling products for asthma, had financial ties to 20 of the 24 members of the 2009 asthma panel, and all 20 were consultant/advisers and/or declared speaker/honoraria ties to GSK [@pmed.1001500-Reddel1].

This study has several important limitations. First, the lack of a comparison group means it is impossible to draw any inference of association between frequency of industry ties and proposals to change disease definitions. The exclusion of common conditions too broad to enable a focussed analysis of single panel publications (e.g., back problems) means it may have missed potentially important examples of changing disease definitions and limits generalizability of findings. The focus on the United States---chosen explicitly because of its globally influential panels such as DSM-V workgroups---also limits generalizability. A fourth limitation is reliance solely on disclosed ties, likely leading to an underestimate of their extent. Finally, we note that while we tried to ensure an exhaustive and multi-layered search strategy, we are unaware of any established method for identifying panel publications that review or propose changes to disease definitions.

Notwithstanding these limitations, the study has strong clinical, research, and policy relevance. Its novel focus on panels reviewing and proposing changes to common disease definitions or diagnostic criteria will help deepen understanding of the nature of what\'s been described as the "modern epidemic" of over-diagnosis [@pmed.1001500-Hoffman1]. Moreover, the group of 16 publications includes influential articles affecting the definition of 14 common conditions and impacting directly on medical policy and practice around the world.

The study findings are consistent with and help augment the evidence-base about industry ties of influential medical professionals. The 2011 systematic review found 56%--87% of clinical guideline writers had conflicts of interest [@pmed.1001500-Norris1], similar to our finding of 75% across disease-defining panels. Kung and colleagues found 71% of guideline committee chairs had conflicts [@pmed.1001500-Kung1], again similar to our findings. While these proportions may reflect the level of ties among medical specialists more generally, they are in stark contrast to IOM 2009 and 2011 reports calling for panels to generally exclude people with conflicts of interest [@pmed.1001500-Lo1],[@pmed.1001500-IOM1]. As reported above, we found no change in the proportion of members disclosing ties in the 2012 publications, after release of both IOM reports.

At least two publications [@pmed.1001500-Thygesen1],[@pmed.1001500-Vakil1] made reference to members believing industry ties did not influence their decision-making, and we make no suggestion to the contrary. Indeed our data do not support any inference industry ties are associated with widening definitions or failure to rigorously assess potential harms of that widening. With anemia in chronic kidney disease, a panel with a high proportion of ties raised thresholds, effectively narrowing the definition [@pmed.1001500-KDIGO1]. There will doubtless be other cases where diseases have been widened by panels of medical specialists without industry ties. Moreover, as Lurie and colleagues found in the context of drug regulation, the financial conflicts of expert advisory committees did not correlate significantly with their voting outcomes [@pmed.1001500-Lurie1]. Medicalization and over-diagnosis are driven by many factors---technological, professional, commercial, legal, and cultural [@pmed.1001500-Moynihan1].

While inferences of association or causation between industry ties and expanding disease definitions cannot be drawn, our findings can be considered in the context of broader evidence about potentially distorting biases associated with widespread industry sponsorship and financial ties in medical research [@pmed.1001500-Schott1]--[@pmed.1001500-Bekelman1], education [@pmed.1001500-Fletcher1], and practice [@pmed.1001500-Lo1], and in relation to "key opinion leaders" who speak and consult for industry [@pmed.1001500-Wang1].

In 1999 Schwartz and Woloshin found changes to definitions of high blood pressure, high cholesterol, diabetes, and overweight would "dramatically inflate disease prevalence" and "ultimately label 75% of the adult U.S. population as diseased" [@pmed.1001500-Schwartz1]. They concluded the "extent to which new 'patients' would ultimately benefit from early detection and treatment of these conditions is unknown. Whether they would experience important physical or psychological harm is an open question." To what extent newly created "patients" produced by widening disease definitions will experience important harms remains a largely unanswered question, over a decade later.

This study did not investigate the merits of the proposed changes to the conditions identified. However, findings that diagnostic thresholds are being lowered by panels dominated by those with financial ties to multiple companies that may benefit directly from those decisions raise questions about current processes of disease definition. While it may be more difficult to locate senior specialists without industry ties, two recent IOM reports have encouraged such a change [@pmed.1001500-Lo1],[@pmed.1001500-IOM1], and models already exist for panels free of such conflicts, including the NIH consensus development program [@pmed.1001500-About1].

Several unanswered questions arise from this study, which could benefit from further investigation. Researchers might fruitfully examine how definitions are changing over time, what dollar amounts are being received from industry by panel members and organisations that auspice them, and how panel proposals impact on potential markets of sponsors. Most importantly enhanced research and policy attention might be directed at designing new processes for reviewing disease definitions, free of financial conflicts of interest and informed by rigorous analysis of benefits and harms.
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ADHD

:   attention deficit hyperactivity disorder

COPD

:   chronic obstructive pulmonary disorder

DSM

:   Diagnostic and Statistical Manual of Mental Disorders

GERD

:   gastroesophageal reflux disease

IOM

:   Institute of Medicine

NIH

:   National Institutes of Health
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